Original Research

Full Title:

HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL PROGNOSTIC FACTORS IN HIGH-GRADE NON-ENDOMETRIOID CARCINOMAS OF THE ENDOMETRIUM (HG-NECs). IS IT POSSIBLE TO IDENTIFY SUB-GROUPS AT INCREASED RISK?

Running Title:

Prognostic Factors in HG-NECs

Authors:

Valerio Gaetano Vellone^{1,2}, Michele Paudice¹, Chiara Maria Biatta¹, Giulia Scaglione¹, Fabio Barra³, Simone Ferrero^{3,4}, Marco Greppi⁵, Laura Paleari⁶, Emanuela Marcenaro⁵ and Gyn DMT^o.

- 1) Dept. of Integrated Diagnostic and Surgical Sciences (DISC), University of Genoa, Italy
- 2) Pathology University Unit, San Martino Hospital, Genoa, Italy
- 3) Dept. of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Italy
- 4) Obstetrics & Gynecology University Unit, San Martino Hospital, Genoa, Italy
- 5) Dept. of Experimental Medicine (DIMES) and Centre of Excellence for Biomedical Research (CEBR), University of Genoa,
- 6) A.Li.Sa., Liguria Region Health Authority, Genoa, Italy

Key words:

Endometrial carcinoma, Immunohistochemistry, Prognosis

*Corresponding Author:

Valerio Gaetano Vellone MD, PhD

Associate Professor of Pathology- Consultant Gynecologic and Fetal Pathologist

Dept. Of Integrated Surgical and Diagnostic Sciences (DISC)

University of Genoa

&

Pathology University Unit

IRCCS Ospedale Policlinico San Martino

Via A. De Toni 14

16132 Genoa, Italy

Tel +390105552162

FAX +390105556605

Valerio.vellone@unige.it

° GYN DMT, a multidisciplinary team of specialist physicians of Ospedale Policlinico San Martino, Genoa, involved in diagnosis and treatment of gynecologic malignancies composed by Serafina Mammoliti (Oncology), Cinzia Caroti (Oncology Clinic), Sergio Costantini (Obstetrics & Gynecology Clinic), Angelo Cagnacci (Obstetrics & Gynecology Clinic), Melita Moioli (Obstetrics & Gynecology Clinic), Maria Grazia Centurioni (Obstetrics & Gynecology), Franco Alessandri (Obstetrics & Gynecology), Luca Dogliotti (Radiology), Maurizio Cosso (Radiology), Michela Marcenaro (Radiation Oncology), Flavio Giannelli (Radiation Oncology), Stefano Di Domenico (General Surgery) and Franco De Cian (General Surgery)

DECLARATIONS

Funding: the current work was granted by University of Genoa Research Funds (FRA)

Conflicts of interest/Competing interests: no conflicts of interest

Availability of data and material (data transparency): the presented data are available to asking scholars

ABSTRACT

Endometrial cancer is an emerging disease with an increase in prevalence of aggressive histotypes in recent years. In the present study potential histopathological and immunohistochemical prognostic markers are investigated

Consecutive cases of high grade non-endometrioid carcinoma (HG-NEC) of the endometrium were considered. Each surgical specimen has been routinely processed, the most representative block has been selected for immunohistochemistry and tested for ER, PR, ki67, p53, E-cadherin, β -catenin, Bcl-2 and cyclin D1. For each immunomarker the percentage of positive tumor cells were evaluated (%) and dichotomized as low and high according to the distribution in the study population. Follow-up was collected for disease-free survival (DFS) and overall survival (OS).

33 cases were eligible: 19 resulted FIGO I-II, 14 resulted FIGO III-IV. 12 patients suffered a recurrent disease (mean follow-up 24.6 months); 8 patients died of the disease (mean follow-up 26.6 months).

Women with recurrent disease demonstrated a significant higher bcl2% ($35.84 \pm 30.96\%$ vs $8.09 \pm 11.56\%$ $p=0.0032$) while DOD patients had higher ki67% ($75 \pm 13.09\%$ vs $58.6 \pm 19.97\%$ $p=0.033$) and bcl2% of border significance ($34.37 \pm 34.99\%$ vs $13 \pm 17.97\%$ $p=0.078$).

As expected FIGO III-IV had a worse DFS (HR=3.34; 95%CI:1.1-10.99; $p=0.034$) and OS (HR=5.19; 95%CI: 1.27-21.14 $p=0.0217$). Bcl2-high patients (bcl2>10%) demonstrated a significant worse DFS (HR=9.11; 95%CI: 2.6-32.4; $p=0.0006$) and OS (HR=7.63; 95%CI:1.7-34; $p=0.0084$); also PR low patients (PR $\leq$ 10%) had a significant worse DFS (HR=3.74; 95%CI:1.2-11.9; $p=0.02$).

HG-NEC represent an heterogeneous group of endometrial aggressive neoplasms with a worrisome prognosis often at an advanced stage at presentation. Bcl2 and PR may represent promising markers to identify a sub-group of patients having an even worse prognosis requiring a careful and close follow-up.

INTRODUCTION

Endometrial carcinoma (EC) is a very common neoplasm among women, being the sixth cause of cancer in the world, the fourth in the USA and in Italy (5% of all tumors). It counts about 320.000 new cases and 76.000 deaths per year. [1]

Its incidence is higher and still increasing in the western industrialized countries, due to the higher incidence of its risk factors and the longevity of the population. [2]

In Italy it is estimated that 1 every 47 women will develop EC in her life. [3]

75% of EC cases are diagnosed in women older than 50 years old. [4] It also appears that as the age of diagnosis increases, also does tumor aggressiveness, being more frequent TP53 mutations and E-cadherin loss of expression. [5]

EC has been long categorized into two major classes, based on clinical-pathological correlations: type I and type II carcinoma. [6]

EC type I, or endometrioid EC, represents the majority of sporadic endometrial carcinomas (70-80%). It is a moderately indolent tumor that generates after prolonged estrogenic stimulation. EC type II, or non-endometrioid EC, is less frequent (about 10–20% of endometrial carcinomas) but more aggressive and usually not related to estrogen excess or to endometrial hyperplasia. They are typically high-grade carcinomas and include non-endometrioid differentiation, most frequently serous, less frequently clear cell, mixed or undifferentiated. [7]

In this contest high grade non-endometrioid endometrial carcinomas (HG-NECs) constitute the histopathologic manifestation of Type II carcinomas.

Since Bockman's classification, numerous molecular studies on endometrial cancer have been carried out and dozens of molecular markers have been proposed over the years as prognostic markers. Recently, TCGA (Cancer Genome Atlas Research Network) has performed genomic, transcriptomic and the proteomic characterization of EC using the most modern array and sequencing-based technologies. As result, a new classification dividing ECs in 4 classes has been proposed representing the future in endometrial carcinoma research. [8]

In the current study we have chosen a small panel of molecules valued with immunohistochemistry, previously proposed as prognostic markers in EC, commonly used in daily practice and available in many labs worldwide.

Overall, steroid hormones (mainly estrogen and progesterone) have been considered to play a key role in the pathogenesis of EC, especially in type I carcinoma. Estrogen (ER) and progesterone receptors (PR) are able to influence prognosis and clinical management as well as they correlate with grading and staging. [9]

ERs are expressed in 60-70% of ECs. They have a pivotal role in the carcinogenesis of type I tumors. [10] Conditions resulting in long lasting unopposed exposure to estrogen (obesity, exogenous hormone replacement therapy, polycystic ovary syndrome, anovulation, and type 1/2 diabetes mellitus) can promote the development of atypical endometrial hyperplasia and increase the risk of EC. [11]

The loss of ER α and PR has been correlated with poor survival, whereas expression of ER β has not shown any clinical pathological correlation. [9] The loss of ER α is associated with high-grade tumors. In contrast, the ER α expression is related to low-grade and low stage of disease.

Progesterone is the physiological estrogen antagonist. [12] It acts by decreasing the risk of developing estrogen-related cancer through several mechanisms, such as reduction of ER and

increase in the metabolic inactivation of estrogen. Thus, estrogen-related endometrial hyperplasia can be treated with progestin therapy. [13]

Ki67 is a nuclear antigen expressed by proliferating cells (phases G1, S, G2, mitosis), but absent in resting cells (G0). High Ki67 expression is related to a more aggressive behavior of cancer. [14]

TP53 oncosuppressor gene (chromosome 17) encodes p53 nuclear protein, a transcriptional factor involved in cell cycle arrest and apoptosis. After DNA damage, p53 accumulates and stops the cell cycle through inhibition of cyclin D1 phosphorylation and, if necessary, by promoting apoptosis through interaction with Bax and Apaf 1 proteins. TP53 mutations are typical of EC type II, in particular of serous carcinoma. [15] The majority of TP53 mutations are missense and lead to the loss of oncosuppressor function. In normal cells p53 is rapidly destroyed and cannot be seen by immunohistochemistry (IHC). Missense mutations are clearly visible by IHC because there is nuclear accumulation of aberrant p53: the most common IHC pattern is widespread and intense nuclear positivity. [16]

β catenin is encoded by CTNNB1 gene (chromosome 3) and the protein mediates the link between actin filaments of the cytoskeleton and transmembrane E-cadherin. The IHC nuclear accumulation of β catenin due to gene mutation are significantly more common in EC type I (31-47%) as compared to EC type II (0-3%). On the contrary, E-cadherin mutation is more frequent in EC type 2. Usually, ECs type 1 with CTNNB1 mutation have favorable prognosis and low stage. [17]

E-cadherin is encoded by the CDH1 gene (chromosome 16) and constitutes another adhesion molecule essential for tight junctions between cells. These molecules mediate the connection between cells through a calcium dependent mechanism. [18]

CDH1 is considered an oncosuppressor gene because it controls cell cohesiveness. Low E-cadherin expression is related to major tumor cells exfoliation and high-risk of peritoneal metastasis. E-cadherin mutation is present in 60% of EC type 2 and in 22% of EC type 1, where it is associated with a more aggressive behavior. The partial or total loss of E-cadherin is reported to be associated with adverse prognosis and short survival. [19]

Bcl-2 is a protein with anti-apoptotic activity, which was identified for the first time in non-Hodgkin's follicular lymphoma. Bcl-2 expression is correlated with many human cancers, including kidney and prostate cancers, thyroid cancer, and non-small cell lung cancer. Loss of BCL2 is associated with independent negative prognostic factors, such as a greater depth of myometrial invasion, aggressive histotype, loss of expression of PR, and advanced FIGO stage at diagnosis. Other studies showed a correlation between loss of BCL2 and risk of lymph node metastasis and recurrence. [20,22]

Cyclin D1, encoded by CCND1, is a proto-oncogene (chromosome 11). Its role is mainly pivotal in the G phase of cell cycle. Cyclin D1 mutation is more typical of EC type 2. [23] Intracytoplasmic protein accumulation, detectable by IHC, has been related to an impairment of proteolytic degradation. [24]

In EC, Cyclin D1 overexpression has a negative prognostic value, and is related with metastatic lymph node involvement. [25]

Rarely β catenin and cyclin D1 are overexpressed together. Some studies showed that cyclin D1 alteration could be an early event in endometrial carcinogenesis, however there is not much difference in its intensity of expression from hyperplasia to EC. [26]

The aim of this study is to identify a sub-group of patients with HG-NECs having a worse prognosis in term of Disease-free Survival (DFS) and Overall Survival (OS) using a limited panel of histopathological and immunohistochemical markers

MATERIALS AND METHODS

We retrospectively considered all patients treated with radical hysterectomy for endometrial carcinoma in our institution for the period 2013-2018. Only cases with a diagnosis of high grade non-endometrioid carcinoma (HG-NEC) were included. Cases undergone to neoadjuvant chemotherapy, previous hormonal therapy, with incomplete data or follow-up were excluded.

The hysterectomy specimens have been routinely fixed and processed to obtain 3 μ m-thick histological sections, finally stained with hematoxylin/eosin. Additional slides have been cut from the most representative paraffin block and tested with a panel of IHC stains including ER α , PR, Ki67, p53, β -catenin, E-cadherin, Bcl-2 and Cyclin-D1. The histopathological examinations have been reported using an institutional protocol.

For IHC we used an automatic immunostainer Benchmark XT (Ventana Medical Systems SA, Strasbourg, France). Antigen-retrieval was obtained with citrate buffer (pH 6) at 90°C for 30 minutes, incubated in primary antibody for 1 hour at 37°C followed by the addition of the polymeric detection system Ventana Medical System Ultraview Universal DAB Detection Kit, counterstained with modified Gill's hematoxylin and mounted in Eukitt.

The tested antibodies are described in table 1.

TABLE 1: LIST OF ANTIBODIES

Marker	clone	manufacturer	dilution	Low	high
ER	6F11	Ventana	pre-diluted	$\leq 10\%$	$> 10\%$
PR	100	Ventana	pre-diluted	$\leq 10\%$	$> 10\%$
ki-67	30-9	Ventana	pre-diluted	$< 60\%$	$\geq 60\%$
p53	DO-7	Ventana	pre-diluted	$\leq 10\%$	$> 10\%$
β -catenin	14	Ventana	pre-diluted	$< 70\%$	$\geq 70\%$
E-cadherin	36	Ventana	pre-diluted	$< 70\%$	$\geq 70\%$
BCL-2	124	Ventana	pre-diluted	$< 60\%$	$\geq 60\%$
Cyclin D1	SP4-R	Ventana	pre-diluted	$< 20\%$	$\geq 20\%$

For all the proposed molecular markers, the staining index (SI), accounting the percentage (%) of positive tumor cells, have been evaluated by two pathologists (VGV and MP) working separately and in blind. Any discrepancy has been discussed at a multiheaded microscope to a final decision.

On the base of the distribution in the study population the SIs of each proposed molecular marker have been dichotomized in two discrete categories named low and high according to the cut-off values illustrated in table 1.

The clinical, pathological and IHC data of the patients enrolled in the study were entered in a Microsoft Excel © spreadsheet.

Discrete variables were compared using the χ^2 test; continuous variables were compared using Kruskal-Wallis test. Correlations between continuous variables was evaluated with Spearman Rank Correlation. Survival univariate analysis was studied with Kaplan-Meier

survival curves. For statistical computation MedCalc© program was used. In all cases a degree of significance of 95% was chosen. In the tables continuous numeric variables are expressed as mean $\pm$ standard deviation while continuous variables as the number of observed cases (percentage).

The proposed study has been authorized by the Liguria Regional Ethic Committee (Prot. Pubbl.HG-NECs_Vellone2021)

RESULTS

In the period considered for the purpose of the study a total of 252 EC were collected; 46 had a diagnosis of HG-NEC (18.25%). A total of 33 cases were considered eligible for the aims of the study.

Our study population was composed by elder women (mean 74.12 $\pm$ 15.53 years; minimum:53; maximum: 93), often coming to surgery in an advanced stage.

HG-NECs represent a heterogeneous group constituted by different histologic types .

The histopathological examination of the surgical specimens frequently showed worrisome features such as infiltrative tumor borders, intratumoral necrosis, and lymph-vascular space invasion. Less frequently moderate/severe desmoplasia or moderate/severe tumor lymphocytic infiltrate were observed. (table 2)

TABLE 2: CLINICAL-PATHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES OF THE STUDY POPULATION. CATEGORICAL VARIABLES

Tab 2.1 Clinical-pathological features

HISTOTYPE	N	%
Mixed	13	39.39
Serous	9	27.27
MMMT	6	18.18
Undiff.	3	9.09
CCC	2	6.06
FIGO	N	%
IA	10	30.30
IB	5	15.15
II	4	12.12
IIIA	2	6.06
IIIC1	6	18.18
IIIC2	5	15.15
IVB	1	3.03
STAGE BINARY	N	%
Local	19	57.58
metastatic	14	42.42
FOLLOW UP DFS	N	%
NO recurrence	21	63.64

Recurrence	12	36.36
FOLLOW UP OS	N	%
Alive	25	75.76
DOD	8	24.24
INVASION		
expansive	11	33.33
infiltrative	22	66.67
DESMOPLASIA		
abs./mild	24	72.73
mod./severe	9	27.27
TIL		
abs./mild	21	63.64
mod./severe	12	36.36
NECROSIS		
absent	7	21.21
present	26	78.79
LVSI		
absent	14	42.42
present	19	57.58

Table 2.1 Immunohistochemistry

ER BIN.		
high	14	42.42
low	19	57.58
PR BIN.		
high	9	27.27
low	24	72.73
KI67 BIN.		
high	23	69.70
low	10	30.30
P53 BIN.		
high	21	63.64
low	12	36.36

B-CATENIN BIN.		
high	27	81.82
low	6	18.18
E-CADHERIN BIN.		
high	29	87.88
low	4	12.12
BCL-2 BIN.		
high	4	12.12
low	29	87.88
CYCLIN D1 BIN.		
high	11	33.33
low	22	66.67

The immunophenotyping of the neoplasms included in the study showed a fairly wide variability in stain index for all proposed molecular markers: ER and PR were in general low as Bcl-2 and Cyclin D1. while ki67. p53. β -catenin and E-cadherin resulted highly expressed. (table 3)

TABLE 3 CLINICAL-PATHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES OF THE STUDY POPULATION. CONTINUOS VARIABLES

	N	Minimum	Maximum	Mean	Median	SD	RSD	SEM	Normal Distr.
Age	33	53	93	74,121	76	10,532	0,1421	1,8334	0,555
FU DFS Dur.	33	1	63	24,848	22	18,3969	0,7404	3,2025	0,1075
FU DOD Dur	33	1	63	27	23	18,0624	0,669	3,1443	0,0443
ER%	33	0	95	25,758	5	33,7065	1,3086	5,8675	0,0501
PR%_	33	0	60	10,788	0	17,3975	1,6127	3,0285	0,0024
ki67%	33	15	90	62,576	60	19,6898	0,3147	3,4276	0,2756
p53%	33	0	100	51,697	60	43,8153	0,8475	7,6273	<0,0001
B-cat%	33	5	100	83,939	100	24,8985	0,2966	4,3343	0,0001
E-cad%	33	20	100	90	100	22,3257	0,2481	3,8864	<0,0001
Bcl-2%	33	0	100	18,182	10	24,4252	1,3434	4,2519	0,0001
Cycl D1%	33	0	100	21,273	15	24,1535	1,1354	4,2046	0,0001

We observed a fairly strong and significant correlation between ER and PR staining index ($\rho=0.716$; $p<0.0001$) and between ki67 and p53 ($\rho=0.541$ $p=0.0012$). (Additional Material 1)

During follow-up (mean DFS follow up duration 24.84 ± 18.39 months; mean OS follow up duration 27 ± 18.06 months). 12 patients (36.36%) recurred after surgery and 8 of them died of the disease (24.24%). as expectable. women with no recurrent disease had a longer follow up (30.28 ± 19.86 months vs 15.33 ± 10.59 months $p=0.037$).

Considering the proposed markers staining index. women with diseases demonstrated significantly higher levels of Bcl-2 as compared to patients with no recurrent disease ($35.84\pm30.96\%$ vs $8.09\pm11.56\%$ $p=0.0032$). No statistically significant differences were demonstrated for the other molecular markers staining indexes. (Additional Material 2)

Patients that died of the disease demonstrated higher levels of ki67 ($75\pm13.09\%$ vs $58.6\pm19.97\%$ $p=0.033$) and levels of Bcl-2 tendentially higher ($34.37\pm34.99\%$ vs $13\pm17.97\%$ $p=0.078$) than patients alive at end of the follow-up. No statistically significant differences were demonstrated for the other molecular markers staining indexes. (Additional Material 3)

On univariate analysis. as expected. patients with metastatic disease at the time of surgery showed a significantly increased risk in both disease recurrence and death by disease. (Table 4.1; Table 5.1; Figure 1)

TABLE 4: DISEASE FREE SURVIVAL UNIVARIATE ANALYSIS

Table 4.1 HISTOPATHOLOGY

HISTOPATHOLOGY	n	%	N	%	p	HR	95% C.I.
Stage binary	NO Recurrence		Recurrence				
<i>metastatic</i>	5	15.15	9	27.27	0.0337	3.48	1.1007 to 10.9943
<i>local</i>	16	48.48	3	9.09			
Invasion	NO Recurrence		Recurrence				
<i>infiltrative</i>	12	36.36	10	30.30	0.1760	2.29	0.6903 to 7.5707
<i>expansive</i>	9	27.27	2	6.06			
Desmoplasia	NO Recurrence		Recurrence				
<i>mod./severe</i>	6	18.18	3	9.09	0.5457	1.46	0.4283 to 4.9718
<i>abs./mild</i>	15	45.45	9	27.27			
Necrosis	NO Recurrence		Recurrence				
<i>present</i>	15	45.45	11	33.33	0.1854	2.45	0.6509 to 9.1917

<i>absent</i>	6	18.18	1	3.03			
TIL	NO Recurrence		Recurrence				
<i>mod./severe</i> <i>abs./mild</i>	8	24.24	4	12.12	0.5861	1.38	0.4319 to 4.4170
	13	39.39	8	24.24			
LVI	NO Recurrence		Recurrence				
<i>present</i> <i>absent</i>	11	33.33	8	24.24	0.3422	1.74	0.5538 to 5.4862
	10	30.30	4	12.12			

Table 4.2 IMMUNOHISTOCHEMISTRY

IHC	n	%	n	%	p	HR	95% C.I.
ER bin.	NO Recurrence		Recurrence				
<i>high</i> <i>low</i>	10	30.3	4	12.1	0.1372	2.4	0.7563 to 7.6371
	11	33.3	8	24.2			
PR bin.	NO Recurrence		Recurrence				
<i>high</i> <i>low</i>	8	24.2	1	3.03	0.0321	3.7	1.1180 to 12.2590
	13	39.4	11	33.3			
p53 bin.	NO Recurrence		Recurrence		0.4098	1.6	0.5025 to 5.4046
<i>high</i> <i>low</i>	12	36.4	9	27.3			
	9	27.3	3	9.09			
ki 67 bin.	NO Recurrence		Recurrence		0.2543	2	0.5991 to 6.9390
<i>high</i> <i>low</i>	13	39.4	10	30.3			
	8	24.2	2	6.06			
E-cad bin.	NO Recurrence		Recurrence				
<i>high</i> <i>low</i>	18	54.5	11	33.3	0.6021	0.6	0.1197 to 3.4242
	3	9.09	1	3.03			

B-cat bin.	NO Recurrence		Recurrence				
<i>high</i>	17	51.5	10	30.3	0.6021	0.6	0.1197 to
<i>low</i>	4	12.1	2	6.06			3.4242
Bcl-2 bin.	NO Recurrence		Recurrence				
<i>high</i>	5	15.2	9	27.3	0.0179	8.6	1.4492 to
<i>low</i>	16	48.5	3	9.09			51.1531
Cycl bin.	NO Recurrence		Recurrence				
<i>high</i>	6	18.2	5	15.2	0.3464	1.8	0.5197 to
<i>low</i>	15	45.5	7	21.2			6.4545

An increased risk of recurrent disease was observed in patients with low PR and high Bcl-2 staining indexes (Table 4.2; Figure1).

The other proposed histopathological and immunohistochemical markers failed to identify a statistically significant risk in term of DFS or OS (Table 4 and 5).

TABLE 5: OVERALL SURVIVAL UNIVARIATE ANALYSIS

Table 5.1 HISTOPATHOLOGY

	n	%	n	%	P	HR	95% C.I.
Stage binary	Alive		DOD				
<i>metastatic</i>	7	21.21	7	21.21	0.0217	5.1856	1.2721 to 21.1382
<i>local</i>	18	54.55	1	3.03			
Invasion	Alive		DOD				
<i>infiltrative</i>	15	45.45	7	21.21	0.2236	2.5651	0.5627 to 11.6940
<i>expansive</i>	10	30.30	1	3.03			
Desmoplasia	Alive		DOD				
<i>mod./severe</i>	6	18.18	3	9.09	0.9788	1.0203	0.2305 to 4.5174
<i>abs./mild</i>	19	57.58	5	15.15			
Necrosis	Alive		DOD				
<i>present</i>	18	54.55	8	24.24	0.1125	NA	NA
<i>absent</i>	7	21.21	0	0.00			
TIL	Alive		DOD				
<i>mod./severe</i>	8	24.24	4	12.12	0.6737	1.3546	0.3298 to 5.5638
<i>abs./mild</i>	17	51.52	4	12.12			
LVSI	Alive		DOD				
<i>present</i>	13	39.39	6	18.18	0.2624	2.2415	0.5465 to 9.1940
<i>absent</i>	12	36.36	2	6.06			

Table 5.2 IMMUNOHISTOCHEMISTRY

IHC	n	%	n	%	P	HR	95% C.I.
ER bin.	Alive		DOD				
<i>high</i>	10	30.30	4	12.12	0.6187	1.4393	0.3431 to 6.0378
<i>low</i>	15	45.45	4	12.12			
PR bin.	Alive		DOD				
<i>high</i>	8	24.24	1	3.03	0.1173	3.1882	0.7473 to 13.6031
<i>low</i>	17	51.52	7	21.21			
p53 bin.	Alive		DOD				
<i>high</i>	15	45.45	6	18.18	0.4592	1.7299	0.4052 to

<i>low</i>	10	30.30	2	6.06			7.3848
ki 67 bin.	Alive		DOD				
<i>high</i>	16	48.48	7	21.21	0.3428	2.1891	0.4337 to
<i>low</i>	9	27.27	1	3.03			11.0500
E-cad bin.	Alive		DOD				
<i>high</i>	22	66.67	7	21.21	0.8738	0.8515	0.1172 to
<i>low</i>	3	9.09	1	3.03			6.1867
B-cat bin.	Alive		DOD				
<i>high</i>	20	60.61	7	21.21	0.9154	0.8869	0.09686 to
<i>low</i>	5	15.15	1	3.03			8.1207
Bcl-2 bin.	Alive		DOD				
<i>high</i>	8	24.24	6	18.18	0.1504	5.6206	0.5345 to
<i>low</i>	17	51.52	2	6.06			59.1001
Cycl bin.	Alive		DOD				
<i>high</i>	8	24.24	3	9.09	0.6959	0.7375	0.1603 to
<i>low</i>	17	51.52	5	15.15			3.3941

FIGURE1:

FIGO I-II

FIGO III-IV

FIGO I-II

FIGO III-IV

Bcl-2 low

Bcl-2 high

PR low

PR high

DISCUSSION

Endometrial carcinoma represents a disease growing in incidence in particular in western countries paralleling the progressive ageing of the population and rising of known risk factors. [27]

In particular the rising of incidence of advanced stages and aggressive histologic types represent a matter of concern for endometrial cancer prevention and treatment.

Only with a better understanding of the molecular events underlying carcinogenesis in the various histotypes of endometrial cancer will it be possible to identify potential prognostic factors and individualized therapy targets.

The recently introduced TGCA classification represent a turn point in endometrial cancer comprehension. Nevertheless, after more than 30 years, the Bokhman and Kurman studies still remain pivotal and relevant. Type I of the traditional classification would encompass cancers belonging to the first three classes of that classification, while Type II of the traditional classification, on the other hand, would encompass tumors of the fourth class. Class 4 Tumors with High Number of Copies are defined as “Serous Like” and are characterized by a high number of aberrations in copy numbers and a low frequency of mutations. They seem to have peculiar mutations frequently involving TP53, FBXW7 and PPP2R1A genes. PTEN and KRAS mutations, typical of low-grade carcinomas with endometrioid histology instead are rare in this kind of tumor. The prognosis of this group appear unfavorable once again. This genomic class includes the majority of serous carcinomas, some of mixed carcinomas and a quarter of endometrioid G3 carcinomas. [28]

TGCA classification represents the future but require advanced and expensive molecular techniques currently available in few laboratories and, as a consequence, seldom used as a guide in a real-life clinical setting. Several groups are currently working on surrogate methods to incorporate TGCA findings in clinical practice. [29]

Histopathological examination still represents the first line in daily diagnostic and immunotesting being relatively unexpensive and well established worldwide, they currently represent the cornerstone of any clinical choice. In this contest HG-NECs require a particular attention in search of potential markers of aggressiveness and future targets for individualized therapies. Our series is small but representative of a heterogeneous group of relatively rare malignancies accumulated by aggressive behavior and poor prognosis. [30]

Comparing our results with the current literature was a challenging task, the results often appear contrasting and very few studies are dedicated exclusively to non-endometrioid high grade carcinomas. Many molecular and morphological prognostic factors have been proposed over the years but it is well established that advanced stage and high grade probably are the most important factors affecting the prognosis. [31,32]

An important bias in many studies is represented by grouping all high-grade endometrial carcinomas in single entity. but high-grade endometrial carcinomas (HG-ECs) seems to have profound differences in clinical-pathological and immunophenotype as compared to HG-NECs. [33,34]

HG-NECs constitutes approximately 20% of the EC and affect the elder population, frequently manifesting in an advanced stage of the disease. HG-NECs often present complex histology, more than half of them show more than one histologic type. the largest subgroup was defined as mixed carcinoma, being composed by two epithelial components with at least one of them serous or clear cell. Another sub-group included MMMT which is composed, by definition, by at least two components, one of them epithelial and high grade. In both the sub-

group the high-grade epithelial component was prominent accounting at least 30% of the entire tumor mass. We support the hypothesis that this high-grade epithelial component represents the “driving force” of the neoplasm. Pure neoplasms were rarer with incidences in line with the literature. [35]

Although HG-NECs represent a heterogeneous group of tumors they could be grouped by the common finding of worrisome features detectable both in hematoxylin-eosin and with the aid of immunohistochemistry.

Histopathological features, widely considered as markers of aggressiveness such as infiltrative tumor borders, intratumoral necrosis, and lymph-vascular space invasion were a common finding in our series, affecting the majority of the cases. Interestingly other worrisome features such as moderate/severe desmoplasia or moderate/severe tumor lymphocytic infiltrate were observed in a minority of cases. [31]

The wide variability observed on tumor cells morphology has been paralleled in the proposed molecular markers staining indexes.

It is well established how ER is expressed in the majority of endometrial and breast carcinomas and its presence is associated with a less aggressive phenotype [36]. on the contrary and as a general rule, HG-NECs show low levels of steroid hormone receptors, confirming their hormone insensitiveness. PR, in contrast to ER, is suggested to be a more predictive factor of disease-free survival [9] and our findings seems to confirm these observations.

The proliferation index, evaluated with ki67, resulted high in some cases, very high in HG-NECs, confirming their aggressive behavior.

TP53 has a fundamental role in differentiating EC subgroups. The mutation of TP53 represents a crucial event in type II endometrial carcinoma carcinogenesis and progression. It is well reported how its accumulation represents a relevant prognostic factor. [28]

As expected in our study population p53 staining index in general was high, failing to identify sub-groups at increased risk of recurrence or death by disease. It should be noted that immunohistochemistry is able to detect only a part of TP53 mutations.

Even tested adhesion molecules β -catenin and E-cadherin failed to identify sub-groups with increased risk. It is reported how low levels of these molecules are associated with metastatic deposition. [38, 39]. In our study population more than half of the patients with low β -catenin and/or low E-cadherin had FIGO III-IV at surgery.

Bcl-2 is a proto-oncogene that has an anti-apoptotic activity, many regulators of the apoptotic process belong to the same family of bcl-2, which consists of proteins that regulate the permeability of the outer mitochondrial membrane. Some of them have an anti-apoptotic function, such as bcl-2, bcl-xl, and bcl-w, while others have a pro-apoptotic activity, like bax, BAD, bak, and bok. [40,41]

Apoptosis is induced by releasing cytochrome c in the cytosol, with the subsequent activation of caspase 9 and caspase 3. [42]

A theory suggests that Rho proteins may have a role in the activation of bcl-2, bcl-1, and Bid. In fact, the inhibition of Rho decreases the expression of anti-apoptotic proteins and increases the levels of the pro-apoptotic protein Bid. It also induces the release of caspase 9 and caspase 3. [43]

The immunohistochemical staining of bcl-2 in non-neoplastic endometrium has a strong variability; it increases in the proliferative phase and decreases in the secretory phase of the menstrual cycle. In these phases, bcl-2 also plays an important role in regulating the cell

differentiation throughout the entire uterine cycle. Some studies have shown that the genes that regulate apoptosis may also be involved in the dysregulation of cell proliferation and death, in the shift from simple to complex hyperplasia, and to adenocarcinoma. [40,41]

The loss of bcl-2 is certainly associated with independent negative prognostic factors, such as deeper myometrial invasion, loss of PR expression, aggressive histotype and advanced FIGO stage. Other studies have shown a correlation between the loss of bcl-2 and the risk of having lymph node metastases and recurrence. [44,45]

In an old study Athanassiadou demonstrated how, on in-print cytological specimens, Bcl-2 expression was associated with a good five year survival. Interestingly also 18 cases of HG-NECs were considered and none of them stained for Bcl-2. [38]

In another, more recent study, Appel et al. failed to find any significant correlation between Bcl-2 expression and histopathologic markers or survival. But again, in this study no distinction between the histologic type is attempted. [22]

Our findings seem to confirm a prognostic role of primary importance for PR and specify the role of Bcl-2 in delimiting a group of patients with greater risk of recurrence. In conclusion we can answer yes to the question in the title. The HG-NECs confirmed their clinical aggressiveness with frequent worrisome aspects. Although marked inter-individual and intratumoral variability has been observed, cases with advanced stage at surgery, low levels of PR and high levels of Bcl-2 have shown a worse DFS. These patients could benefit from a close follow-up with thorough controls and more aggressive treatments.

ACKNOWLEDGEMENTS

Special thanks to Giorgia Anselmi, Silvana Bevere, Simona Pigozzi and Laura Zito for technical support

REFERENCES

1. B. Stewart e C. Wild. World cancer report. World Health Organization. 2014.
2. Lortet-Tieulent J, Ferlay J, Bray F, Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. *J Natl Cancer Inst* 2018;110:354–361
3. AIOM. «Numeri del cancro 2018
4. Schottenfeld D. Epidemiology of endometrial neoplasia. *J Cell Biochem Suppl.* 1995;23:151-9.
5. Gonzalez-Rodilla I, Boix M, Verna V, Muñoz AB, Estévez J, Jubete Y, Schneider J. Patient age and biological aggressiveness of endometrial carcinoma. *Anticancer Res.* 2012 May;32(5):1817-20.
6. Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol.* 1983 Feb;15(1):10-7
7. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. *Virchows Arch.* 2004 Mar;444(3):213-23.
8. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013 May 2;497(7447):67-73.
9. Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. *Eur J Cancer.* 2007 Nov;43(16):2434-44
10. Ryan AJ, Susil B, Jobling TW, Oehler MK. Endometrial cancer. *Tissue Res* 2005 Oct;322(1):53-61.
11. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauredó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, Castellvi S, Ramon y Cajal J, Gil-Moreno A, Xercavins J, Alameda F, Reventós J. Novel molecular profiles of endometrial cancer-new light through old windows. *J Steroid Biochem Mol Biol.* 2008 Feb;108(3-5):221-9
12. Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. *Cancer Res.* 2001 Jun 1;61(11):4576-82
13. Zannoni GF, Monterossi G, De Stefano I, Gargini A, Salerno MG, Farulla I, Travaglia D, Vellone VG, Scambia G, Gallo D. The expression ratios of estrogen receptor α (ER α) to estrogen receptor β 1 (ER β 1) and ER α to ER β 2 identify poor clinical outcome in endometrioid endometrial cancer. *Human Pathology* (2013) 44. 1047–1054
14. Scholzen T, Gerdes J (March 2000). "The Ki-67 protein: from the known and the unknown". *J. Cell. Physiol.* 182 (3): 311–22
15. Moll UM, Chalas E, Auguste M, Meaney D, Chumas J Uterine papillary serous carcinoma evolves via a p53-driven pathway. *Hum Pathol.* 1996 Dec;27(12):1295-300.].
16. Singh N, Piskorz AM, Bosse T, Jimenez-Linan M, Rous B, Brenton JD, Gilks CB, Köbel M. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. *J Pathol.* 2020;250(3):336-345. <https://doi.org/10.1002/path.5375>.

17. Norasate Samarnthai. Kevin Hall and I-Tien Yeh. Molecular Profiling of Endometrial Malignancies. *Obstet Gynecol Int.* 2010;2010:162363
18. Schlosshauer PW. Ellenson LH. Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. *Mod Pathol.* 2002 Oct;15(10):1032-7
19. Holcomb K. Delatorre R. Pedemonte B. McLeod C. Anderson L. Chambers J. E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium. *Obstet Gynecol.* 2002 Dec;100(6):1290-5. doi: 10.1016/s0029-7844(02)02391-8. PMID: 12468176.
20. Geisler JP. Geisler HE. Wiemann MC. Zhou Z. Miller GA. Crabtree W. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. *Gynecol Oncol.* 1998 Nov;71(2):305-7
21. Saegusa M. Kamata Y. Isono M. Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. *J Pathol.* 1996 Nov;180(3):275-82.
22. Appel ML. Edelweiss MI. Fleck J. Rivero LF. Rivoire WA. Mônico HI. Dos Reis R. P53 and BCL-2 as prognostic markers in endometrial carcinoma. *Pathol Oncol Res.* 2008 Mar;14(1):23-30.
23. Catasus L. Gallardo A. Prat J. Molecular genetics of endometrial carcinoma. *DIAGNOSTIC HISTOPATHOLOGY* 15:12 2009
24. Moreno-Bueno G. Rodríguez-Perales S. Sánchez-Estévez C. Hardisson D. Sarrió D. Prat J. Cigudosa JC. Matias-Guiu X. Palacios J. Cyclin D1 gene (CCND1) mutations in endometrial cancer. *Oncogene* (2003) 22. 6115–6118
25. Liang S. Mu K. Wang Y. Zhou Z. Zhang J. Sheng Y. Zhang T. CyclinD1, a prominent prognostic marker for endometrial diseases. *Diagn Pathol.* 2013 Aug 15;8:138
26. Choudhury M. Bansal S. Expression of cyclin D1 in endometrial hyperplasia and endometrial carcinoma. *Indian J Pathol Microbiol.* 2007 Oct;50(4):708-10
27. Binder PS. Mutch DG. Update on prognostic markers for endometrial cancer. *Womens Health (Lond).* 2014 May;10(3):277-88. doi: 10.2217/whe.14.13. Review.
28. Vellone. V.G., Peñuela. L., Carbone. R., Biatta. C.M., Spina. B., Barra. F., Ferrero. S. Molecular pathology of endometrial carcinoma and its histopathological correlations: Beyond a dualistic vision? (2018) *Endometrial Cancer: Risk Factors, Management and Prognosis*. pp. 25-68
29. Carlson J. McCluggage WG Reclassifying endometrial carcinomas with a combined morphological and molecular approach. *Curr Opin Oncol.* 2019 Sep;31(5):411-419.
30. Soslow RA. Bissonnette JP. Wilton A. Ferguson SE. Alektiar KM. Duska LR. Oliva E. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. *Am J Surg Pathol.* 2007 Jul;31(7):979-87.
31. Prat J. Prognostic parameters of endometrial carcinoma. *Hum Pathol.* 2004 Jun;35(6):649-62.
32. Steiner E. Eicher O. Sagemüller J. Schmidt M. Pilch H. Tanner B. Hengstler JG. Hofmann M. Knapstein PG. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. *Int J Gynecol Cancer.* 2003 Mar-Apr;13(2):197-203

33. Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A, Gallo D. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. *Virchows Arch.* 2010 Jul;457(1):27-34.
34. Alvarez T, Miller E, Duska L, Oliva E. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma? *Am J Surg Pathol.* 2012 May;36(5):753-61.
35. Tavassoli F.A., Devilee P. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon 2003
36. Ito K, Utsunomiya H, Yaegashi N, Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma--new developments in potential endocrine therapy for endometrial cancer. *Endocr J.* 2007 Dec;54(5):667-79.
37. Zheng X, Du XL, Jiang T. Prognostic significance of reduced immunohistochemical expression of E-cadherin in endometrial cancer-results of a meta-analysis. *Int J Clin Exp Med.* 2015 Oct 15;8(10):18689-96.
38. Athanassiadou P, Petrakakou E, Liossi A, Nakopoulou L, Zerva C, Dimopoulos A, Athanassiades P. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. *Acta Cytol.* 1999 Nov-Dec;43(6):1039-44.
39. Mell LK, Meyer JJ, Tretiakova M, et al. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. *Clin Cancer Res.* 2004;10(16):5546-5553.
40. Samaranthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. *Obstet Gynecol Int.* 2010;2010:162363.
41. Prat J, Gallardo A, Cuatrecasas M, Catasús L. Endometrial carcinoma: pathology and genetics. *Pathology.* 2007 Feb;39(1):72-87
42. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. *Oncogene.* 1998 Apr 30;16(17):2265-82..
43. Hippenstiel S, Schmeck B, N'Guessan PD, Seybold J, Krüll M, Preissner K, Eichel-Streiber CV, Suttrop N. Rho protein inactivation induced apoptosis of cultured human endothelial cells. *Am J Physiol Lung Cell Mol Physiol.* 2002 Oct;283(4):L830-8.
44. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. *Gynecol Oncol.* 1998 Nov;71(2):305-7.
45. Saegusa M, Kamata Y, Isono M, Okayasu I. Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. *J Pathol.* 1996 Nov;180(3):275-82.

FIGO I-II

FIGO III -IV

FIGO I-II

FIGO III-IV

Bcl-2 low

Bcl-2 high

PR low

PR high